Roche (SWX: RO, ROG) announced today that it is partnering with Diabeloop to advance insulin pump therapy management.
Basel, Switzerland-based Roche said in a news release that the partnership will create new opportunities to lower the burden of constant insulin dose adjustment for those with diabetes while also improving therapy outcomes.
Roche also said the partnership with Paris-based Diabeloop marks its first step into the field of automated insulin delivery as it continues to put forth its strategy of integrated personalized diabetes management.
“Everybody at Roche Diabetes Care is excited about the new partnership with Diabeloop. The technology of Diabeloop, based on a self-learning algorithm, is unique. We are convinced that the potential of the hybrid closed-loop systems will contribute to a more efficient and personalized approach of diabetes management,” Roche Diabetes Care global head Marcel Gmuender said in the release. “For more than three decades, we have been committed to supporting people with diabetes with a range of different insulin pump technologies. Throughout the years, we have always aimed to give people with diabetes choice, so that they can select the best therapy solutions to suit their needs. Together with Diabeloop, we are again expanding the choice of options available to people with diabetes, by embarking on our journey of automated insulin delivery.”
“Reliable insulin delivery is a critical component in Diabeloop’s hybrid closed-loop systems embedding therapeutic artificial intelligence,” added Diabeloop founder & co-CEO Erik Huneker. “The accuracy and reliability of Roche’s insulin pump portfolio perfectly fits our vision to personalize therapy to the physiology and lifestyle of people with diabetes, helping them to spend less time managing diabetes while improving time in range.”
“We are looking forward to partnering with Roche and work together to individualize diabetes management,” concluded Marc Julien, co-CEO at Diabeloop.
